Literature DB >> 27461758

Atopic dermatitis, naevi count and skin cancer risk: A meta-analysis.

Sara Gandini1, Ignazio Stanganelli2, Domenico Palli3, Vincenzo De Giorgi4, Giovanna Masala5, Saverio Caini6.   

Abstract

BACKGROUND: The risk of skin malignancy among atopic dermatitis (AD) patients is not well established.
OBJECTIVE: We reviewed the epidemiological evidence on the association between AD, naevi count, and the risk of cutaneous melanoma and keratinocyte skin cancer (KSC).
METHODS: We included all studies that compared the naevi count and the risk of skin cancer (melanoma and/or KSC) between AD patients and unaffected individuals. We calculated summary relative risks (SRRs) and 95% confidence intervals (CI) through random effects models; explored correlates of between-studies heterogeneity using sub-group and sensitivity analysis; and assessed publication bias using a funnel-plot-based approach.
RESULTS: The number of common naevi larger ≥2mm on the whole body was consistently lower among AD patients vs. unaffected individuals when measured by trained health professionals. The risk of melanoma was not increased among AD patients (SRR=0.77, 95%CI 0.44-1.35, I2=85%). We found a significantly increased risk of basal cell cancer (BCC) (SRR=1.34, 95%CI 1.03-1.75, I2=24.0%) but not for squamous cell cancer (SRR=1.91, 95% CI 0.74-4.91, I2=0.0%); however, only a few papers adjusted for phenotypic characteristics and/or sunlight exposure. We found no evidence of publication bias.
CONCLUSIONS: AD patients may be at increased BCC risk; however, methodological limitations prevented from drawing definitive conclusions. Despite the lack of strong scientific evidence, AD patients should avoid excessive sun exposure, regularly perform skin self examination, and consult a doctor in case of a suspicious skin lesion.
Copyright © 2016 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Atopic dermatitis; Cutaneous melanoma; Keratinocyte skin cancer; Meta-analysis; Naevi count

Mesh:

Year:  2016        PMID: 27461758     DOI: 10.1016/j.jdermsci.2016.07.009

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  5 in total

Review 1.  Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments.

Authors:  Alex J McCraw; Jitesh Chauhan; Heather J Bax; Chara Stavraka; Gabriel Osborn; Melanie Grandits; Jacobo López-Abente; Debra H Josephs; James Spicer; Gerd K Wagner; Sophia N Karagiannis; Alicia Chenoweth; Silvia Crescioli
Journal:  Cancers (Basel)       Date:  2021-09-04       Impact factor: 6.575

2.  Increased Regulatory T Cells and Decreased Myeloid-Derived Suppressor Cells Induced by High CCL17 Levels May Account for Normal Incidence of Cancers among Patients with Atopic Dermatitis.

Authors:  Sohshi Morimura; Makoto Sugaya; Tomonori Oka; Hiraku Suga; Tomomitsu Miyagaki; Yuichiro Tsunemi; Yoshihide Asano; Shinichi Sato
Journal:  Int J Mol Sci       Date:  2021-02-18       Impact factor: 5.923

Review 3.  A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.

Authors:  Thomas Bieber; Eugen Feist; Alan D Irvine; Masayoshi Harigai; Ewa Haladyj; Susan Ball; Walter Deberdt; Maher Issa; Susanne Grond; Peter C Taylor
Journal:  Adv Ther       Date:  2022-09-05       Impact factor: 4.070

Review 4.  Autoimmunity as an Etiological Factor of Cancer: The Transformative Potential of Chronic Type 2 Inflammation.

Authors:  Chris M Li; Zhibin Chen
Journal:  Front Cell Dev Biol       Date:  2021-06-21

Review 5.  Comorbidities of Atopic Dermatitis: Beyond Rhinitis and Asthma.

Authors:  Yuki M F Andersen; Alexander Egeberg; Lone Skov; Jacob P Thyssen
Journal:  Curr Dermatol Rep       Date:  2017-01-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.